Patient-Specific Radiation Dosimetry of <sup>99m</sup>Tc-HYNIC-Tyr<sup>3</sup>-Octreotide in Neuroendocrine Tumors

Grimes, Joshua; Celler, Anna; Birkenfeld, Bożena; Shcherbinin, Sergey; Listewnik, Maria H.; Piwowarska-Bilska, Hanna; Mikołajczak, Renata; Zorga, Piotr

doi:10.2967/jnumed.111.088203

Cited by 41 publications

(40 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This method was also adapted for purposes of calculating doses with the goal of limiting bone marrow radiation dose. In a study of 12 patients undergoing 99m Tc-EDDA/ HYNIC-Tyr3-octreotide imaging of NETs, SPECT/CT afforded the calculation of radiation dosimetry identifying the highest absorbed radiation doses to liver, spleen, kidneys and bladder (160).…”

Section: Somatostatin Receptor Scintigraphy With Spect/ct For Stamentioning

confidence: 99%

“…Agreement (k): Planar k ϭ 0.59, SPECT k ϭ 0.74, SPECT/CT k ϭ 0.86 Change in management(151),(150) SPECT/CT changes management in 13.9%-40% of patients Attenuation-correction(153) Attenuation-corrected SPECT/CT leads to increased uptake in 30% of lesions with no change to diagnostic performance Additional benefits of SPECT/CT(95,155,182,324),(155),(159,160) Improved reader confidence, allows single time-point imaging at 24 h, can perform patient-specific and tumor-…”

mentioning

confidence: 98%

See 1 more Smart Citation

Endocrine Scintigraphy with Hybrid SPECT/CT

et al. 2014

View full text Add to dashboard Cite

Nuclear medicine imaging of endocrine disorders takes advantage of unique cellular properties of endocrine organs and tissues that can be depicted by targeted radiopharmaceuticals. Detailed functional maps of biodistributions of radiopharmaceutical uptake can be displayed in three-dimensional tomographic formats, using single photon emission computed tomography (CT) that can now be directly combined with simultaneously acquired cross-sectional anatomic maps derived from CT. The integration of function depicted by scintigraphy and anatomy with CT has synergistically improved the efficacy of nuclear medicine imaging across a broad spectrum of clinical applications, which include some of the oldest imaging studies of endocrine dysfunction.

show abstract

Section: Somatostatin Receptor Scintigraphy With Spect/ct For Stamentioning

confidence: 99%

mentioning

confidence: 98%

Endocrine Scintigraphy with Hybrid SPECT/CT

et al. 2014

View full text Add to dashboard Cite

show abstract

“…99m Tc-Hydrazinonicotinamide-Tyr(3)-octreotide ( 99m Tc-TOC) is increasingly gaining acceptance as a new radiopharmaceutical for diagnosis of SSTR-expressing tumours [90, 91]. 18 F-FDA (fluorodopamine) PET has been developed at the National Institutes of Health in Bethesda, MD, and is currently used as an experimental tracer at the NIH only.…”

Section: Other Pet Tracersmentioning

confidence: 99%

EANM 2012 guidelines for radionuclide imaging of phaeochromocytoma and paraganglioma

Taïeb

Timmers

Hindié

et al. 2012

Eur J Nucl Med Mol Imaging

225

143

View full text Add to dashboard Cite

Purpose Radionuclide imaging of phaeochromocytomas (PCCs) and paragangliomas (PGLs) involves various functional imaging techniques and approaches for accurate diagnosis, staging and tumour characterization. The purpose of the present guidelines is to assist nuclear medicine practitioners in performing, interpreting and reporting the results of the currently available SPECT and PET imaging approaches. These guidelines are intended to present information specifically adapted to European practice. Methods Guidelines from related fields, issued by the European Association of Nuclear Medicine and the Society of Nuclear Medicine, were taken into consideration and are partially integrated within this text. The same was applied to the relevant literature, and the final result was discussed with leading experts involved in the management of patients with PCC/PGL. The information provided should be viewed in the context of local conditions, laws and regulations. Conclusion Although several radionuclide imaging modalities are considered herein, considerable focus is given to PET imaging which offers high sensitivity targeted molecular imaging approaches.

show abstract

“…Grimes et al 14 reported the mean effective dose of Tc-99m HYNIC-TOC to be 4.6±1.1 mSv. The effective dose of 18 F-FDG-PET/CT and whole-body Tc-99m MIBI imaging for adults is 0.019 (0.070) and 0.015 (0.056) mSv/MBq (rem/mCi), respectively 15,16.…”

Section: Discussionmentioning

confidence: 99%

Clinical value of technetium-99m-labeled octreotide scintigraphy in local recurrent or metastatic medullary thyroid cancers

Sağer

Kabasakal²,

Ocak³

et al. 2013

Nuclear Medicine Communications

View full text Add to dashboard Cite

AimVarious studies have been conducted for determining the most optimal method for the early diagnosis of local recurrent or distant metastatic thyroid cancers. The aim of this study was to evaluate the clinical utility of technetium-99m (Tc-99m)-labeled octreotide derivatives in the detection of recurrence or distant metastases in medullary thyroid cancer patients and to compare the lesions with those detected using 18F-fluorodeoxyglucose (18F-FDG)-PET and Tc-99m MIBI studies in the same patient group.Patients and methodsSixteen medullary thyroid cancer patients [two male and 14 female; mean age 52.0±14.1 years (range 13–72 years)] were included in this study. All patients underwent a whole-body scan 1 and 4 h after injection with octreotide derivatives and single photon emission computed tomography images were taken of the sites suspicious for metastasis. The lesions seen in Tc-99m HYNIC octreotide studies were compared with those seen in 18F-FDG-PET and Tc-99m MIBI studies.ResultsAmong the Tc-99m-labeled octreotide scintigraphy studies, nine were evaluated as true positive (56.2%) and one was evaluated as false positive (6.2%); six were false negative (37.5%). In 16 patients, the total number of lesions seen on octreotide scintigraphy was 21. Thirteen of the 16 patients underwent 18F-FDG-PET imaging. Of the 13 patients studied, 10 showed true-positive (76.9%) and three showed false-negative (23.1%) results. The total number of lesions seen on 18F-FDG-PET was 23. The Tc-99m MIBI study yielded positive results in seven of 16 patients (43.7%) and negative results in nine patients (56.3%). The total number of lesions on Tc-99m MIBI was 12.ConclusionThe Tc-99m-labeled somatostatin receptor scintigraphy analogs HYNIC-tyrosine octreotide and HYNIC-TATE are useful imaging alternatives in somatostatin receptor-expressing thyroid cancers. Radiolabeling using these analogs is easy and they are readily available for routine use.

show abstract

Patient-Specific Radiation Dosimetry of ^99mTc-HYNIC-Tyr³-Octreotide in Neuroendocrine Tumors

Cited by 41 publications

References 16 publications

Endocrine Scintigraphy with Hybrid SPECT/CT

Endocrine Scintigraphy with Hybrid SPECT/CT

EANM 2012 guidelines for radionuclide imaging of phaeochromocytoma and paraganglioma

Clinical value of technetium-99m-labeled octreotide scintigraphy in local recurrent or metastatic medullary thyroid cancers

Contact Info

Product

Resources

About

Patient-Specific Radiation Dosimetry of 99mTc-HYNIC-Tyr3-Octreotide in Neuroendocrine Tumors

Cited by 41 publications

References 16 publications

Endocrine Scintigraphy with Hybrid SPECT/CT

Endocrine Scintigraphy with Hybrid SPECT/CT

EANM 2012 guidelines for radionuclide imaging of phaeochromocytoma and paraganglioma

Clinical value of technetium-99m-labeled octreotide scintigraphy in local recurrent or metastatic medullary thyroid cancers

Contact Info

Product

Resources

About

Patient-Specific Radiation Dosimetry of ^99mTc-HYNIC-Tyr³-Octreotide in Neuroendocrine Tumors